Pressure healing for safer wounds
The first mechanically powered incisional negative pressure wound therapy device.
A single-use ultraportable solution delivering proven constant negative pressure to reduce complications and improve the healing of surgical wounds.
Sustainable medical technologies for all suitable patients
Sustainable medical technologies for all suitable patients
Antonio D’Angelo & Andrea Cazzulani found out that an advanced medication with proven results was striving to become the standard of care because of several issues such as high price and unhandiness of current devices. Incisional negative pressure was loosing to absorbent wound dressing even if clinical data showed dramatic superiority.
Antonio & Andrea joined forces and in 2020 founded Medicud, invented and developed a novel easy-to-use and discreet single use i-NPWT device that can cut down therapy cost and reduced ecological footprint.
Medicud aims to become the global leader of sustainable medical technologies.
Antonio D’Angelo & Andrea Cazzulani found out that an advanced medication with proven results was striving to become the standard of care because of several issues such as high price and unhandiness of current devices. Incisional negative pressure was loosing to absorbent wound dressing even if clinical data showed dramatic superiority.
Antonio & Andrea joined forces and in 2020 founded Medicud, invented and developed a novel easy-to-use and discreet single use i-NPWT device that can cut down therapy cost and reduced ecological footprint.
Medicud aims to become the global leader of sustainable medical technologies.
Motivated Organization
World changing mentality
ESG complaint
SDG driven
Shareholders
Value maximization
Customers
Customers
Value maximization
Commercial excellence
Customer solution
Meet the team
Meet the team
ANTONIO NUNZIO D’ANGELO
ANTONIO NUNZIO D’ANGELO
FOUNDER & CEO
Engineer in material science from EPFL with past experience as manager of concurrent analysis in industry and researcher in flexible electronics for bio systems.
FOUNDER & CEO
Engineer in material science from EPFL with past experience as manager of concurrent analysis in industry and researcher in flexible electronics for bio systems.
ANDREA CAZZULANI
FOUNDER & CTO
Aerospace engineer from Sapienza covered supply chain and engineering roles in large cap companies
ANDREA CAZZULANI
FOUNDER & CTO
Aerospace engineer from Sapienza covered supply chain and engineering roles in large cap companies
ANTONIO NUNZIO D’ANGELO
FOUNDER & CEO
Engineer in material science from EPFL with past experience as manager of concurrent analysis in industry and researcher in flexible electronics for bio systems.
ANDREA CAZZULANI
FOUNDER & CTO
Aerospace engineer from Sapienza covered supply chain and engineering roles in large cap companies
CRISTINA SCARANO
CRISTINA SCARANO
R&D ENGINEER
Biomedical engineer from Politecnico di Torino.
R&D ENGINEER
Biomedical engineer from Politecnico di Torino.
FILIPPO
FORTE
QA/RA
Biologist with more than 8 years of experience in regulatory affairs for medical devices.
FILIPPO FORTE
QA/RA
Biologist with more than 8 years of experience in regulatory affairs for medical devices.
CRISTINA SCARANO
R&D ENGINEER
Biomedical engineer from Politecnico di Torino.
FILIPPO FORTE
QA/RA
Biologist with more than 8 years of experience in regulatory affairs for medical devices.
MARIO MILITELLO
MARIO MILITELLO
COMMERCIAL MANAGER
30 years of international experience in medical device sales direction
COMMERCIAL MANAGER
30 years of international experience in medical device sales direction
MARIO MILITELLO
COMMERCIAL MANAGER
30 years of international experience in medical device sales direction
Info for investors
Patended technology.
1 granted and 4 pending
Patended technology.
1 granted and 4 pending
Potential market of more than 230 million majors incisional surgeries performed yearly, valued 11 billion €, still largely untapped
Potential market of more than 230 million majors incisional surgeries performed yearly, valued 11 billion €, still largely untapped
Clinical phase company
Clinical phase company
Market entry anticipated in 2024
Supported by
Partners
